ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ImmuneOnco Biopharmaceuticals has successfully completed the placement of over 33 million new H shares, raising approximately HK$229.73 million. The proceeds will be used to advance clinical studies for treatments targeting various cancers, including non-small cell lung cancer and triple-negative breast cancer. This strategic move aims to bolster the company’s research and development efforts in China.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.